Medical device company Clinical Laserthermia Systems (CLS) has signed a collaboration agreement with Alligator Bioscience regarding future treatment strategies for tumor diseases.
Both companies develop cancer therapies with immuno-modulating effects but their approaches are different. According to them these differences in approach opens up for novel possibilities and potential synergies.
“The collaboration concerns early phase research and will initially focus on pre-clinical experiment,” says Jakob Axelsson, Head of Research at CLS. “These experiment have been planned during a long time and we expect to start working on this during this summer.”